BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 29723602)

  • 1. Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.
    Toth LN; de Abreu FB; Tafe LJ
    Hum Pathol; 2018 Aug; 78():138-143. PubMed ID: 29723602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
    Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
    J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.
    Tafe LJ; Pierce KJ; Peterson JD; de Abreu F; Memoli VA; Black CC; Pettus JR; Marotti JD; Gutmann EJ; Liu X; Shirai K; Dragnev KH; Amos CI; Tsongalis GJ
    Neoplasia; 2016 Sep; 18(9):577-83. PubMed ID: 27659017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution.
    Rodriguez EF; De Marchi F; Lokhandwala PM; Belchis D; Xian R; Gocke CD; Eshleman JR; Illei P; Li MT
    Cancer Med; 2020 Jun; 9(12):4386-4394. PubMed ID: 32333643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain.
    Lopez GY; Reitman ZJ; Solomon D; Waldman T; Bigner DD; McLendon RE; Rosenberg SA; Samuels Y; Yan H
    Biochem Biophys Res Commun; 2010 Jul; 398(3):585-7. PubMed ID: 20603105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations.
    Linos K; Tafe LJ
    Histopathology; 2018 Dec; 73(6):963-968. PubMed ID: 30003571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
    Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
    Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical Detection and Molecular Characterization of IDH-mutant Sinonasal Undifferentiated Carcinomas.
    Mito JK; Bishop JA; Sadow PM; Stelow EB; Faquin WC; Mills SE; Krane JF; French CA; Fletcher CDM; Hornick JL; Sholl LM; Jo VY
    Am J Surg Pathol; 2018 Aug; 42(8):1067-1075. PubMed ID: 29683816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
    Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D
    J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis.
    Saiji E; Pause FG; Lascombes P; Cerato Biderbost C; Marq NL; Berczy M; Merlini L; Rougemont AL
    Virchows Arch; 2019 Nov; 475(5):625-636. PubMed ID: 31240473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma.
    Hartman DJ; Binion D; Regueiro M; Schraut W; Bahary N; Sun W; Nikiforova M; Pai RK
    Am J Surg Pathol; 2014 Aug; 38(8):1147-56. PubMed ID: 25029120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
    Kato Kaneko M; Ogasawara S; Kato Y
    Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinico-neuropathological features of isocitrate dehydrogenase 2 gene mutations in lower-grade gliomas.
    Wang LM; Li Z; Piao YS; Cai YN; Zhang LY; Ge HJ; Xu WW; Lu DH
    Chin Med J (Engl); 2019 Dec; 132(24):2920-2926. PubMed ID: 31833906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
    Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
    Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and clinical characteristics of IDH mutations in Chinese NSCLC patients and potential treatment strategies.
    Chen S; Zhu H; Jin M; Yuan H; Liu Z; Li J; Zhang X; Meng L; Li T; Diao Y; Gao H; Hong C; Zhu X; Zheng J; Li F; Niu Y; Ma T; Li X
    Cancer Med; 2022 Nov; 11(22):4122-4133. PubMed ID: 35526267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
    van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP
    Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma.
    Dogan S; Frosina D; Fayad M; de Oliveira TB; Alemar B; Rosenblum M; Tang LH; Hameed M; Xu B; Ghossein RA; Chute DJ; Weigelt B; Jungbluth AA
    Mod Pathol; 2019 Feb; 32(2):205-215. PubMed ID: 30206411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular investigation of isocitrate dehydrogenase gene (IDH) mutations in gliomas: first report of IDH2 mutations in Indian patients.
    Das BR; Tangri R; Ahmad F; Roy A; Patole K
    Asian Pac J Cancer Prev; 2013; 14(12):7261-4. PubMed ID: 24460285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.